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Abstract
Introduction: Co-occurrence with other chronic diseases may influence the progression of dementia, especially in case of
multiple chronic diseases. We aimed to verify whether multimorbidity influenced cognitive and daily functioning during
nine years after dementia diagnosis compared with the influence in persons without dementia.
Methods: In the Kungsholmen Project, a population-based cohort study, we followed 310 persons with incident dementia
longitudinally. We compared their trajectories with those of 679 persons without dementia. Progression was studied for
cognition and activities of daily life (ADLs), measured by MMSE and Katz Index respectively. The effect of multimorbidity and
its interaction with dementia status was studied using individual growth models.
Results: The mean (SD) follow-up time was 4.7 (2.3) years. As expected, dementia related to both the decline in cognitive
and daily functioning. Irrespective of dementia status, persons with more diseases had significantly worse baseline daily
functioning. In dementia patients having more diseases also related to a significantly faster decline in daily functioning. Due
to the combination of lower functioning in ADLs at baseline and faster decline, dementia patients with multimorbidity were
about one to two years ahead of the decline of dementia patients without any co-morbidity. In persons without dementia,
no significant decline in ADLs over time was present, nor was multimorbidity related to the decline rate. Cognitive decline
measured with MMSE remained unrelated to the number of diseases present at baseline.
Conclusion: Multimorbidity was related to baseline daily function in both persons with and without dementia, and with
accelerated decline in people with dementia but not in non-demented individuals. No relationship of multimorbidity with
cognitive functioning was established. These findings imply a strong interconnection between physical and mental health,
where the greatest disablement occurs when both somatic and mental disorders are present.
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Introduction
In absence of disease modifying treatment, slowing down the
progression of dementia by lessening the cognitive and functional
decline is a possible strategy to limit the burden of the dementing
disorders [1]. An increasing body of evidence suggests an
interrelatedness between physical and cognitive functioning [2–
4]. Clinical experience suggests that dementia patients with
physical co-morbidity progress faster than patients without co-
morbidity. This relation may offer a ‘‘window’’ for slowing down
dementia progression.
Unfortunately, the relationship between dementia progression
and multimorbidity is not frequently studied in the literature. The
results of cross-sectional studies have shown contradictory results
[5–9]. There are only a few longitudinal studies concerning the
effect of multimorbidity on dementia progression, which also
provided contradictory results with respect to the influence of
multimorbidity on dementia progression [10–13]. The severity
and the progression of dementia are not one-dimensional
constructs: the clinical presentation of a dementia at a certain
point in time is the result of the functioning on several domains.
Global cognitive and daily functioning are core to the diagnosis of
dementia and also core outcomes in dementia severity measures
such as the Clinical Dementia Rating Scale [14,15]. Taking this
into account, in the current study we studied the effect of
multimorbidity on both cognitive and daily functioning in
dementia. It is likely that multimorbidity may also affect daily
functioning independently of the presence of dementia [16], and
such an effect may also be present for cognitive functioning [17].
Therefore, in addition to studying the effect of the presence of
multimorbidity on functioning in dementia patients, we were
interested to understand if multimorbidity affected progression in
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daily and cognitive functioning differently in persons with and
without a dementia.
With this study we aimed to explore the role of multimorbidity,
defined as the presence of two or more chronic diseases, on the
change in cognitive and daily function over up to nine years of
follow up in a large population-based sample of persons with
incident dementia and to compare these findings with the effects in
non-demented persons.
Figure 1. Study flow chart*. * BL, FU1, FU2, and FU3 indicate the original baseline and consecutive follow up assessments of the Kungsholmen
Project. LTFU= lost to follow up because the participant withdrew from the study or could not be contacted. Died= lost to follow up because the
participant died. Censored= the participant reached the final Kungsholmen Project Follow up assessment used in this study.
doi:10.1371/journal.pone.0084014.g001
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Methods
The study population was recruited among all 2368 inhabitants
in the Kungsholmen Parish of Stockholm, Sweden who were 75
years and older at 31 december 1987 (born in or before 1912) [18],
of whom 1810 persons agreed to participate in the Kungsholmen
Project (KP). Eligible for the current study were participants who
were free from dementia at the Kungsholmen Project baseline
assessment (n = 1475) and who participated in the first KP follow
up assessment (n = 989). The baseline assessment (BL) was carried
out between 1987 and 1989 and was followed by four
examinations spaced approximately three years apart (FU1-4).
Ethics Statement and Data Sharing Statement
The Kungsholmen Project has been approved by the Ethics
Committee of the Karolinska Institute. The data from the
Kungsholmen Project are available upon request.
Of the 989 persons who participated in the first follow up, 310
people were diagnosed with dementia at first (n = 127), second
(n = 112), or third follow up (n = 71). The progression of dementia
over time was studied by using data from the last follow up
assessment in the Kungsholmen Project before dementia onset and
onwards, until either a participant died, withdrew informed
consent, or reached the third follow up. In order to be included in
this study, at least two assessments (one before dementia onset and
at least one after dementia onset) had to be available.
The current study enrolled participants from the last clinical
assessment carried out in the Kungsholmen Project before a
subject developed dementia, because several demented partici-
pants had already a huge drop in dementia-related outcome
measures over the time frame in which the dementia occurred. It is
likely that the observed drop was at least to some extent part of the
post-onset trajectory.
In order to compare the trajectories of the incident dementia
cases with the trajectories of non-demented persons, we construct-
ed control trajectories for the 679 participants who participated in
the first follow up and remained dementia-free throughout the
follow up. As dementia onset is a random event, the construction
of the trajectories of the non-demented persons was done by
randomly assigning one of the assessments they participated in
(BL-FU2) as the starting point of their follow up trajectories in this
study.
Data collection. At all examinations in the Kungsholmen
Project the data were collected following the same standardised
protocols [18,19], with the exception of the measurement of
disability using the Katz Index [20]. At BL in the Kungsholmen
Project the participants were asked several questions about their
functioning with regards to the six activities of daily living (ADL)
that the Katz Index assesses, and afterwards this information was
recoded into three levels of functioning for each of the six abilities
(requiring no help, some help, or much help). At the follow ups the
participants were directly asked to rate their functioning in each of
the six domains on a three point scale (0,1 or 2). This approach
resulted in an ADL score which ranges from 0 (‘no help’ in all six
domains) to 12 (‘much help’ in all six domains). If the participant
was not able to answer the questions reliably, an informant was
contacted.
Dementia diagnosis. Diagnosis of dementia was based on
DSM-III-R-criteria and was defined as memory impairment
accompanied by impairment in abstract thinking, judgment, other
higher cortical function or personality change, where the resulting
cognitive disturbance interfered with work, social activities or
Table 1. Sample characteristics at baseline*.
Non-demented
persons (n=679)
Persons with incident
dementia (n =310)
p-value for difference
between groups
Age (years); mean (SD) 83 (4.7) 85 (4.5) ,0.001
Female sex; n (%) 501 (73.8) 258 (83.2) 0.001
Low education (#7 years of formal
education); n (%){
315 (46.6) 174 (56.3) 0.005
Institutional living; n (%) 7 (1.0) 12 (3.9) 0.003
MMSE; mean (SD)` 27 (2.1) 25 (3.3) ,0.001
ADL; n (%) No disability 443 (66.3) 187 (60.5) 0.04
Disability in 1 function 167 (25.0) 82 (26.5)
Disability in 2 functions 39 (5.8) 20 (6.5)
Disability in 3+ functions 19 (2.8) 20 (6.5)
ADL score; mean (SD)1 0.8 (1.4) 1.2 (1.9) ,0.001
Morbidity; n (%) No chronic diseases
(other than dementia)
551 (81.1) 225 (72.6) ,0.001
One chronic disease
(other than dementia)
96 (14.1) 50 (16.1)
Two or more chronic diseases
(other than dementia)
32 (4.7) 35 (11.3)
No of morbidities; mean (SD) 0.3 (0.6) 0.4 (0.9) ,0.001
Follow up time (years); mean (SD)|| 4.8 (2.4) 4.4 (2.0) 0.009
*Characteristics of the sample at the moment of entry in this study, unless otherwise stated.
{Education as was established at the original baseline assessment of the Kungsholmen Project.
`Range 0–30, where a higher score indicated better functioning.
1Range 0–12, where a lower score indicated better functioning.
||Follow up time since the follow up assessment at entry in this study.
doi:10.1371/journal.pone.0084014.t001
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relationship with others and without these cognitive changes
occurring exclusively in the setting of delirium [14]. If memory
impairment was evident but dysfunction of a second cognitive
ability was questionable, the additional category ‘questionable
dementia’ was used [21]. These persons were regarded as non-
demented in this study.
Multimorbidity. Multimorbidity was defined as any co-
occurrence of two or more chronic conditions in the same
individual [22]. The number of chronic conditions at the
assessment from which the participants were enrolled in the
current study was counted in the same manner as in our previous
studies on multimorbidity [23], except for some modifications. We
only used the information from the computerized Stockholm
Inpatient Register to detect chronic disorders because disease
information taken from the other sources was not available for all
assessments [24]. In the analyses, multimorbidity was operationa-
lised as ‘‘no disease’’, ‘‘one disease’’, and ‘‘two or more diseases’’,
because only a few persons had three or more diseases present at
baseline (n = 22: 12 persons with and 10 persons without incident
dementia).
Primary outcome measure. We were primarily interested
in dementia progression in a broad, clinical sense. Therefore, as
the primary outcome measures we modelled the change over time
in the two major dimensions of functioning – cognitive and daily
functioning – in the analyses. Global cognitive functioning was
studied using MiniMental State Examination and functioning in
Activities of Daily Living (ADLs) were measured using Katz ADL
items [20,25].
Statistical analysis. Characteristics as present at inclusion
were presented using means and proportions – as appropriate – for
the participants grouped by dementia diagnosis. Individual growth
modelling was used to study the progression of cognitive and ADL
functioning over time and to study the influence of dementia,
multimorbidity, and their interaction on the progression of the
outcome [26]. Time was treated as time (years) since the last KP
assessment before dementia diagnosis for participants whom
developed dementia and time since the KP assessment that was
randomly chosen as the starting point of the follow up trajectory
for participants without dementia. For each of the two outcome
measures ADL score and MMSE, we first identified which
unconditional individual growth model fitted the data best: linear
growth or curvilinear growth. The aim of the first step was to find
the models that best explained the within person change over time
in each of the outcome measures. As such, the trajectory of each
participant over time was characterized by an intercept and one or
more slope parameters. These parameters are called the individual
Table 2. Occurrence of Separate Conditions among Participants with one or more Diseases (n = 213) at Inclusion in this Study.
Condition, n (%) Participants with one disease, n =146 Participants with two or more diseases, n =67
Hip fracture 14 (1) 8 (12)
Osteo arthritis 17 (12) 9 (13)
Rheumatoid arthritis 3 (2) 2 (3)
Atrial fibrillation 4 (3) 11 (16)
Cardiomyopathy 1 (1)
Chronic rheumatic heart disease 1 (1)
Heart failure 15 (10) 29 (43)
Hypertension 1(1) 6 (9)
Ischemic heart disease 9 (6) 17 (25)
Cerebrovascular disease 8 (5) 11 (16)
Diabetes 17 (12) 15 (22)
Disorder of thyroid 1 (1)
Cholelithiasis 1 (1) 2 (3)
Diverticula of intestine 2 (3)
Functional digestive disorder 1 (1) 3 (4)
Anemia 4 (3) 5 (7)
Chronic obstructive pulmonary disease 20 (14) 16 (24)
Cancer 15 (1) 7 (10)
Deafness 1 (1) 2 (3)
Disorders of the eye 8 (5) 2 (3)
Epilepsy 1 (1) 1 (1)
Parkinson disease 5 (7)
Peripheral nerve system 1 (1)
Alcohol dependence syndrome 1 (1)
Depression 4 (3) 6 (9)
Schizophrenia 1 (1)
Calculus of kidney and ureter 1 (1)
Hyperplasia of prostate 1 (1) 2 (3)
doi:10.1371/journal.pone.0084014.t002
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growth factors. Next, several predictors (dementia, age, sex,
education, multimorbidity) were added one-by-one to assess
whether they significantly (alpha ,0.05) explained the (between
person) variance in the individual growth factors. Age (years) and
multimorbidity (0, 1, or 2 or more diseases) were taken into
account in the models as age and multimorbidity at the last KP
assessment before dementia diagnosis for participant whom
developed dementia and at the KP assessment that was randomly
chosen as the starting point of the follow up trajectory for
participants without dementia. In the final models, dementia
diagnosis, multimorbidity and their interaction was modelled to
assess whether the influence of multimorbidity on cognitive and
ADL functioning progression was specifically related to persons
suffering of dementia or was also present in non-demented
persons. These analyses were done unadjusted as well as adjusted
for age, sex, education and living situation.
Results
We followed 989 persons (310 persons with incident dementia
and 679 persons who served as non-demented controls) longitu-
dinally for a mean (SD) follow up period of 4.7 (2.3) years (figure 1).
The participants had a mean (SD) age of 83 (4.7) at inclusion into
this study and were in majority female (n = 759, 76.7%).
Compared to non-demented persons, at inclusion in this study,
dementia patients were older, more often female, had lower
MMSE scores, had more ADL disabilities, and more often suffered
from multimorbidity (Table 1). The dementia was in 251 (81% of
310) of the participants of Alzheimer type and in 59 (19% of 310)
of non-Alzheimer type. Among the whole study group, 213 (22%
of 989) participants had at least one or more diseases at the
moment of inclusion in the current study (table 2). Among the 146
participants with one disease, most prevalent were chronic
obstructive pulmonary disease (20, 14%), diabetes (17, 12%),
osteo arthritis (17, 12%) and heart failure (15, 10%). Among the 67
participants with two or more diseases, heart failure (29, 43%),
ischemic heart disease (17, 25%), chronic obstructive pulmonary
disease (16, 24%) and diabetes (15, 22%) were most prevalent.
When we modelled the within person change over time in
cognitive and daily functioning, the best fitting models contained
both a linear and a quadratic individual growth factor (daily
functioning: table 3, model 1; cognitive functioning: table 4, model
4), a random intercept (the variance component called ‘‘in initial
status’’ in table 3 and 4), and a random slope (the variance
component called ‘‘in linear rate of change’’ in table 3 and 4). A
random quadratic slope was tested but did not further improve the
fit of the unconditional growth models and was therefore
constrained to zero by removal from the models [26].
The associations of dementia, multimorbidity and their
interaction with the outcomes Katz ADL and MMSE were first
examined without adjustment (models 2 and 5, tables 3 and 4
respectively) and successively after adjustment for age, sex,
Table 3. The Results of Fitting Different Individual Growth Models in Functioning in Activities of Daily Living*.
Model 1: Unconditional
individual growth model
Model 2: Effect of dementia,
morbidity and their interaction,
unadjusted
Model 3: Effect of dementia,
morbidity and their interaction,
adjusted{
Parameter Estimate p-value Estimate p-value Estimate p-value
FIXED EFFECTS
Intercept` 0.89 ,0.001 0.69 ,0.001 0.44 0.51
Dementia 0.16 0.21 0.05 0.66
Multimorbidity (0, 1, 2+) 0.37 0.003 0.29 0.01
Dementia*multimorbidity 0.35 0.06 0.28 0.11
Linear rate of change1 0.07 0.06 20.06 0.15 0.02 0.82
Dementia 0.14 0.10 0.07 0.42
Multimorbidity (0, 1, 2+) 0.04 0.63 0.01 0.89
Dementia*multimorbidity 0.31 0.01 0.34 0.006
Quadratic rate of change || 0.03 ,0.001 0.01 0.04 0.02 0.21
Dementia 0.10 ,0.001 0.10 ,0.001
Multimorbidity (0, 1, 2+) 0.002 0.89 0.003 0.79
Dementia*multimorbidity 20.04 0.03 20.04 0.03
RANDOM EFFECTS: VARIANCE COMPONENTS
In initial status 0.83 ,0.001 0.79 ,0.001 0.43 0.005
In linear rate of change 0.24 ,0.001 0.11 ,0.001 0.17 ,0.001
Covariance 0.22 ,0.001 0.17 ,0.001 0.10 ,0.001
Within person (residual) 2.10 ,0.001 2.05 ,0.001 1.98 ,0.001
*Functioning in Activities of Daily Living (ADL) was assessed with the six Katz ADL items scored on a three point scale (0 = no help needed, 1 = some help needed,
2 =much help needed), resulting in a score ranging 0–12, where higher scores indicate more help needed.
{Adjusted for age, sex, education and living situation at the first assessment with which this participant was included in this study. For participants who developed
dementia this was their status at the last KP assessment before dementia was diagnosed and for participants who remained without dementia the KP assessment that
was randomly chosen as the starting point of the follow up trajectory for this study.
`For model 2 and 3 this row indicates the initial status for participants without dementia or morbidity.
1For model 2 and 3 this row indicated the linear rate of change for participants without dementia or morbidity.
||For model 2 and 3 this row indicated the quadratic rate of change for participants without dementia or morbidity.
doi:10.1371/journal.pone.0084014.t003
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education and living situation (models 3 and 6, tables 3 and 4
respectively). Dementia patients had a decline in daily functioning
that continues to grow steeper with time, compared to participants
not having dementia, as can be seen from the quadratic decline
rate in ADL estimated as 0.10 (p,0.001) higher per squared year
(year*year) since dementia onset in participants who developed
dementia. At early stage follow up, if a dementia patient had one
more comorbidity, this was associated with an additional 0.34
points per year (p = 0.006) in the linear ADL rate of change (model
3, table 3). However, as indicated by a quadratic fixed factor
dementia*multimorbidity with a point estimate of20.04 (p = 0.03,
model 3, table 3), the quadratic decline rate in people with
dementia and one more disease is lower as compared to
participants with dementia with less disease. Persons without
dementia had a worse baseline ADL score if they have more
diseases, but their daily functioning over time was not significantly
affected by multimorbidity.
To summarize how all the effects added up, the mean growth
curves predicted by model 3 for a non-demented person with 0, 1
or 2 or more diseases and for a dementia patient with 0, 1 or 2 or
more diseases were displayed graphically in figure 2. As explained
above, whereas slopes for having 0, 1 or 2 or more diseases did not
differ significantly for a non-demented person, the corresponding
slopes did significantly differ for a dementia person. Further,
whereas the intercepts differed significantly for having 0, 1 or 2 or
more diseases, they did not differ significantly more when the
person had dementia. We can observe that – irrespective of
comorbidity – for participants with dementia the ADL decline
rates were higher in the late period of follow up than those in early
follow up. In addition, we can observe that at early follow up
among dementia patients ADL decline rates were highest for
people with two or more diseases, whereas at late follow up ADL
decline rates were highest for dementia patients without diseases.
At the end of follow up, ADL disability levels were comparable for
all dementia patients.
Participants with as well as without dementia showed a
significant quadratic decline in cognition as indicated by a rate
of 20.05 (p = 0.02) for participants without dementia (table 4,
model 6 and figure 3). However, dementia patients had a
significantly lower cognitive function already at baseline (21.88,
p,0.001) and – as expected – a steeper decline over time with an
estimated increase in linear change rate in dementia patients of
21.91 (p,0.001). The effects of the number of diseases on
cognitive functioning over time in participants with dementia were
in the same direction as for daily functioning, but were much
smaller and non significant.
Discussion
This study showed that baseline chronic multimorbidity was
significantly associated to accelerated decline in daily functioning
but not in cognition in dementia patients. Whereas this effect was
present in persons suffering from dementia, no effect could be
Table 4. The Results of Fitting Different Individual Growth Models in Cognitive Functioning*.
Model 4: Unconditional
individual growth model
Model 5: Effect of dementia,
morbidity and their
interaction, unadjusted
Model 6: Effect of dementia,
morbidity and their interaction,
adjusted{
Parameter Estimate p-value Estimate p-value Estimate p-value
FIXED EFFECTS
Intercept` 26.44 ,0.0001 27.25 ,0.001 27.73 ,0.001
Dementia 22.30 ,0.001 21.88 ,0.001
Multimorbidity (0, 1, 2+) 20.27 0.17 20.04 0.83
Dementia*multimorbidity 20.20 0.49 20.20 0.47
Linear rate of change1 20.78 ,0.001 20.18 0.004 20.17 0.16
Dementia 21.97 ,0.001 21.91 ,0.001
Multimorbidity (0, 1, 2+) 0.01 0.92 0.02 0.84
Dementia*multimorbidity 20.19 0.35 20.27 0.17
Quadratic rate of change|| 20.02 0.01 20.02 0.05 20.05 0.02
Dementia 0.02 0.27 0.02 0.38
Multimorbidity (0, 1, 2+) 20.01 0.54 20.01 0.46
Dementia*multimorbidity 0.04 0.18 0.06 0.09
RANDOM EFFECTS: VARIANCE COMPONENTS
In initial status 3.81 ,0.001 2.29 ,0.001 1.41 ,0.001
In linear rate of change 1.15 ,0.001 0.31 ,0.001 0.29 ,0.001
Covariance 1.551 ,0.001 0.51 ,0.001 0.54 ,0.001
Within person (residual) 4.26 ,0.001 4.64 ,0.001 4.54 ,0.001
*Cognitive functioning was assessed with MiniMental State Examination (MMSE), score ranging 0–30, where lower scores indicate worse functioning.
{Adjusted for age, sex, education and living situation at the first assessment with which this participant was included in this study. For participants who developed
dementia this was their status at the last KP assessment before dementia was diagnosed and for participants who remained without dementia the KP assessment that
was randomly chosen as the starting point of the follow up trajectory for this study.
`For model 2 and 3 this row indicates the initial status for participants without dementia or morbidity.
1For model 2 and 3 this row indicated the linear rate of change for participants without dementia or morbidity.
||For model 2 and 3 this row indicated the quadratic rate of change for participants without dementia or morbidity.
doi:10.1371/journal.pone.0084014.t004
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identified in non-demented persons. Due to the combination of
lower functioning in ADLs at baseline and faster decline, dementia
patients with multimorbidity were about one to two years ahead of
the decline of dementia patients without any co-morbidity.
Remarkably, in persons without dementia, multimorbidity was
not associated to hastened decline in ADLs, but was only
associated with baseline ADL funtioning. We could not show
convincingly any effects of the presence of additional diseases on
cognitive function measured with MMSE. These findings have
potential implications for clinical practice, as they stress the
relevance of optimal treatment of co-morbidities in dementia
patients.
These results are also relevant for our understanding of the
pathophysiology of late-life dementia, because they suggest – as
has been done earlier [2–4] – that physical factors may be involved
in the clinical presentation of dementia. This is in line with the
model outlined by Fotuhi et al and other researchers who
suggested a dynamic polygon hypothesis [27,28]. The dynamic
polygon hypothesis provides a framework for thinking about aging
and dementia that departs from the linear model proposed by the
amyloid cascade hypothesis: it considers several pathological
processes (e.g. amyloid aggregation, vascular damage) interlinked
with positive or negative consequences of environmental exposures
(e.g. exercise, obesity) to be affecting the size and functioning of the
brain [28]. Multimorbidity may very well be one of the factors that
add to the dynamic polygon ultimately resulting in the dementia
phenotype. It is remarkable that multimorbidity did not affect
change over time in ADLs when dementia was absent. These
findings imply a strong interconnection between physical and
mental health, where the greatest disablement occurs when both
somatic and mental disorders are present.
When we compare these results with those of the study done by
MacDonald et al which used Kungsholmen Project data on
disease trajectories in more advanced stages of cognitive decline
and in which multimorbidity did not affect the rate of progression
[11], we may conclude that it is typically in the earliest phase of
dementia onset that multimorbidity is of influence. Also, their
study only looked at cognitive function measured with MMSE. In
our as well as in another recent longitudinal population based
cohort of persons with dementia baseline disease burden was not
shown to be related to MMSE decline [13]. On the other hand, in
a clinical cohort of dementia patients, disease burden was
associated with MMSE decline [12]. In that study, comorbidity
also tended to associate with an increased ADL functional decline,
but without the effects being statistically significant. Further study
is needed, both to better understand whether, how and when
multimorbidity is part of the complex pathophysiology of
dementia and how it is related to dementia progression, as well
as to see whether optimizing the treatment of co-morbidities will
result in a slower dementia progression. These studies could first
Figure 2. Mean Growth Curves for ADL Functioning.Mean Growth Curves for ADL Functioning* (Higher Score Indicates Worse Functioning) for
Persons with Incident Dementia with 0 (black, dotted), 1 (black, dashed) or 2+ (black, solid) Diseases and Persons without Dementia with 0 (grey,
dotted), 1 (grey, dashed) or 2+ (grey, solid) Diseases as Predicted by a Model 3 in Table 3. * Functioning in Activities of Daily Living (ADL) was assessed
with the six Katz ADL items scored on a three point scale (0 = no help needed, 1 = some help needed, 2 =much help needed), resulting in a score
ranging 0–12, where higher scores indicate more help needed.
doi:10.1371/journal.pone.0084014.g002
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seek to replicate our results in other observational studies with an
additional focus on whether multimorbidity differently affects
different aspects of disease progression and acts differently in
different dementia subtypes. Also the studies could focus on
whether there are discrete (clusters of) diseases that influence
dementia disease progression or whether the effect of multi-
morbidity is independent of the diseases present.
Using data from Kungsholmen Project, we were able to study
our research question in a sample of incident dementia cases taken
from a general population who were systematically assessed for the
presence or absence of dementia at several points in time and were
followed over a long period of time of almost five years on average.
This increased the external validity of these results, in comparison
to for example clinical samples of dementia patients where the
sampling is more prone to selective recruitment. Using KP data,
we were also able to compare the effect of disease burden on
cognitive and ADL decline in dementia patients with its effect in
non-dementia controls. This is important, because in this way we
could show that the faster decline in ADLs in dementia patients
with multimorbidity was not independently associated with
multimorbidity alone.
Despite the strengths of performing this study using data from a
large population-based longitudinal cohort study such as KP, the
study design also came with some limitations. The current study
operationalized multimorbidity as the time-invariant number of
diseases present at time is zero (KP assessment before time frame
in which dementia became apparent for participants who
developed incident dementia or a randomly chosen KP assessment
for those participants not developing dementia). A time-varying
multimorbidity status may be a better measure because it can
better capture a study subject’s true status. The same may be true
for measures that do not only capture the number but also the
severity of the conditions present, such as the Cumulative Illness
Rating Scale-Geriatrics [29]. We were only able to use disease
information taken from hospital admissions to establish the
number of diseases present at baseline. This resulted in a smaller
portion of people with multimorbidity than generally found.
However, multimorbidity prevalence is known to be highly
variable and dependent on the way it is determined [30]. This
entails a general limitation of the external validity of studies into
multimorbidity and also the results of our study cannot be
immediately generalized to settings where multimorbidity was
operationalized differently. By using only hospital admission
diagnoses we counted the presence of multimorbidity that was
less often present but probably also more severe. Unfortunately,
the Kungsholmen Project does not provide sufficient information
Figure 3. Mean Growth Curves for Cognitive Functioning. Mean Growth Curves for Cognitive Functioning* (Higher Score Indicates Better
Functioning) for Persons with Incident Dementia with 0 (black, dotted), 1 (black, dashed) or 2+ (black, solid) Diseases and Persons without Dementia
with 0 (grey, dotted), 1 (grey, dashed) or 2+ (grey, solid) Diseases as Predicted by a Model 6 in Table 4. *Cognitive functioning was assessed with
MiniMental State Examination (MMSE), score ranging 0–30, where lower scores indicate worse functioning.
doi:10.1371/journal.pone.0084014.g003
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on the treatment the participants received for their chronic
conditions to allow study into whether they were optimally treated
and how this related to dementia progression. Participants of the
Kungsholmen Project received usual care as it was provided by the
Swedish healthcare system in the period 1987 to 1998.
Also important was that KP provided relatively few FU
assessments that were also performed with relatively long time
periods in between (approximately every three years). Further
studies – such as the one from Solomon et al. [12] – using clinical
samples taken, for example, from memory clinics (despite the
results being more easily distorted by methodological problems
such as selection bias) may complement population-based follow
up studies, since in these clinical samples it is more feasible to have
frequent FU assessments. Clinical samples may also offer more
timely and more detailed description of dementia subtypes, than
KP was able to provide. Nosological classifications of dementia
syndromes have shown to change, and this is specifically difficult to
handle in long running cohorts such as KP. Therefore, in the
current study we refrained from studying how the effect of
multimorbidity is different for different nosological subtypes and
studied participants with a dementia as one group: the criteria for
a dementia syndrome have remained fairly stable over the years.
The long period over which we followed participants also meant a
challenge to measuring cognitive functioning. MMSE is a measure
that is fairly insensitive to small and subtle cognitive changes and
certainly does not reflect the complexity of cognitive functioning.
Measures that capture the complexity and subtleties of cognitive
functioning better than MMSE were available in the Kungholmen
Project, but not for all time points and the complete cohort. On
other hand, empirical studies in dementia patients have also shown
that over longer follow ups – as we had in our study – MMSE does
capture cognitive change [31] and MMSE has been used
previously for studying heterogeneity in cognitive trajectories in
persons with dementia [12,13].Selective attrition due to health and
survival has been observed in previous longitudinal analyses of
cognition [32] and may also have affected our results. To better
understand the influence of follow status, as sensitivity analyses we
reran the analyses presented in model 2 (table 3) and model 3
(table 4) respectively, now taking into account the statistical
interaction of all fixed effects presented with loss to follow up due
to death. Although this cannot definitely rule out that selective
attrition resulted in biased estimates, the estimates for the fixed
effects were comparable in the sensitivity analyses.
Next, the difficulty with any disease with a gradual onset, is that
it is difficult to exactly frame when the disease becomes incident.
Close assessment of the individual progression trajectories showed
that many dementia cases already experienced a considerable
decline before the FU assessment at which the diagnosis was
formalized. Since we did not want to miss this early part of the
trajectories in our analyses, we decided to use the last FU
assessment before the dementia became incident as our baseline.
Despite this, dementia cases still had worse cognitive scores than
non-dementia controls already at baseline. This was in line with
previous observations that dementia patients begin to experience
declines in cognitive performance years before a formal diagnosis
is made [33].
Our findings indicate that multimorbidity was associated with
considerably accelerated decline in daily function amongst persons
with dementia and may very well be one the physical factors that
add to the dementia phenotype. The greatest disablement seemed
to occur when both mental and physical impairments were
present. At early follow up, the rate of ADL decline was largest in
dementia patients with multimorbidity, at late follow up, the rate
of ADL decline may be largest in dementia patients without
multimorbidity at dementia onset.
This is a result that deserves further exploration. If it can be
shown that optimizing the treatment of co-morbidities in dementia
can improve the early prognosis of dementia patients, multi-
morbidity may offer one of the ‘‘windows’’ for the prevention of
complications of dementia.
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